Summary：**Chris Johnson's ALS Diagnosis Revives Ice Bucket Challenge, Experts Warn Awareness Isn’t Enough**

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Chris Johnson's ALS Diagnosis Revives Ice Bucket Challenge, Experts Warn Awareness Isn’t Enough**
*ALS is a hot topic this summer in the wake of Chris Johnson's diagnosis. But what can be done besides the revival of the Ice Bucket Challenge? The answer might surprise you…*

---

### Introduction
When former NFL star Chris Johnson announced his amyotrophic lateral sclerosis (ALS) diagnosis earlier this month, social media feeds lit up with the familiar splash of ice‑water videos. The Ice Bucket Challenge, which raised over $220 million for ALS research in 2014, has resurfaced as fans and fellow athletes pour buckets of cold water over their heads in solidarity. While the renewed visibility is welcome, neurologists and advocacy groups caution that viral moments alone cannot sustain the fight against a disease that still lacks a cure.

### Key Developments
Johnson’s public disclosure has sparked a surge in online searches for “ALS symptoms” and “ALS treatment options,” pushing the condition into the top‑trending health queries on Google this week. Several major sports leagues have pledged matching donations for every challenge video posted, and a handful of biotech firms have announced accelerated timelines for gene‑therapy trials. Meanwhile, the ALS Association reported a 35 % increase in direct donations during the first two weeks of the challenge’s revival, though the average gift size remains modest compared with the peak years of 2014‑2015.

### Industry Analysis
Experts point out that awareness campaigns excel at driving short‑term spikes in funding but often fail to translate into long‑term research infrastructure. Dr. Maya Patel, a neurologist at the National Institute of Neurological Disorders, notes that “the bottleneck isn’t public interest; it’s the sustained investment needed for preclinical work and clinical trials.” Funding gaps persist in areas such as biomarker development and patient‑centric care models, which require multi‑